deltatrials
Unknown EARLY_PHASE1 NCT04326036

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection

Sponsor: Black Tie Medical, Inc.

Conditions COPD Coronavirus Infection Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Pulmonary Alveolar Proteinosis Viral Pneumonia
Interventions Centricyte 1000 IV Deployment Of cSVF In Sterile Normal Saline IV Solution Liberase Enzyme (Roche) Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Sterile Normal Saline for Intravenous Use
Updated 8 times since 2020 Last updated: Feb 21, 2023 Started: Mar 25, 2020 Primary completion: Aug 1, 2023 Completion: Jan 31, 2024

This EARLY_PHASE1 trial investigates COPD and Coronavirus Infection and is currently ongoing. Black Tie Medical, Inc. leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

8 versions recorded

  1. Mar 2025 — Present [monthly]

    Unknown EARLY_PHASE1

    Status: Enrolling By Invitation → Unknown

  2. Sep 2024 — Mar 2025 [monthly]

    Enrolling By Invitation EARLY_PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Enrolling By Invitation EARLY_PHASE1

  4. Mar 2023 — Jul 2024 [monthly]

    Enrolling By Invitation EARLY_PHASE1

  5. Apr 2022 — Mar 2023 [monthly]

    Enrolling By Invitation EARLY_PHASE1

    Status: Recruiting → Enrolling By Invitation

▶ Show 3 earlier versions

  1. Jan 2021 — Apr 2022 [monthly]

    Recruiting EARLY_PHASE1

  2. Nov 2020 — Jan 2021 [monthly]

    Recruiting EARLY_PHASE1

    Status: Enrolling By Invitation → Recruiting

  3. Apr 2020 — Nov 2020 [monthly]

    Enrolling By Invitation EARLY_PHASE1

    First recorded

Mar 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Black Tie Medical, Inc.
  • Robert W. Alexander, MD
Data source: Black Tie Medical, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Stevensville, United States